S. N . IU PA C na m es C om m on na m es St ru ct ur e Pl an tp ar t( co un tr y) Re fe re nc es 15 6 3- (4 -H yd ro xy ph en yl )- 2- pr op en oi ca ci d p- C ou m ar ic ac id OH O O H W ho le (Ja pa n) [9 9] 15 7 2- M et ho xy -4 -( 2- pr op en -1- yl )- ph en ol Eu ge no l OO H Le av es an d ro ot s( Ja pa n) [9 9] 15 8 3- (4 -H yd ro xy -3 -m et ho xy ph en yl )- 2- pr op en oi ca ci d Fe ru lic ac id O O H O H O W ho le (Ja pa n) [9 9] 15 9 3- (3 ,4 -D ih yd ro xy ph en yl )- 2- pr op en oi c ac id Ca ffe ic ac id O H O O H O H W ho le an d ae ria l( Ja pa n) [7 5, 99 ] 16 0 3- Pr op yl -3 [( 2, 4, 5- tr im et ho xy ph en yl )- m et ho xy ]- 2, 4- pe nt an ed io ne 3- Pr op yl -3 -( 2, 4, 5- tr im et ho xy )b en zy lo xy - pe nt an -2 ,4 -d io ne O O O O O O Le av es (In di a) [1 00 ] 16 1 3- (3 ,4 -D ih yd ro xy ph en yl )- 2- pr op en oi ca ci d, et hy le ste r Ca ffe at e, et hy l O O O H O H N ot fo un d (T ai w an ); w ho le (T ai w an ) [4 3, 45 ,8 4] Evidence-Based Complementary and Alternative Medicine 31 Ta bl e 7: C on tin ue d. S. N . IU PA C na m es C om m on na m es St ru ct ur e Pl an tp ar t( co un tr y) Re fe re nc es 16 2 2- [[ 3- (3 ,4 -D ih yd ro xy ph en yl )- 1-o xo -2 - pr op en yl ]o xy ]- 3, 4- di hy dr ox y- 2- m et hy l-b ut an oi ca ci d d- Er yt hr on ic ac id , 2- O -c aff eo yl -2 -C -m et hy l O H O O H H O O O O H O H Le av es (Ja pa n) [1 01 ] 16 3 2- [[ 3- (3 ,4 -D ih yd ro xy ph en yl )- 1-o xo -2 - pr op en yl ]o xy ]- 3, 4- di hy dr ox y- 2- m et hy l-b ut an oi ca ci d, m et hy le ste r d- Er yt hr on at e, m et hy l 2- O -c aff eo yl -2 -C -m et hy l O O O H H O O O O H O H Le av es (Ja pa n) [1 01 ] 16 4 3- [[ 3- (3 ,4 -D ih yd ro xy ph en yl )- 1-o xo -2 - pr op en yl ]o xy ]- 2, 4- di hy dr ox y- 2- m et hy l-b ut an oi ca ci d, m et hy le ste r d- Er yt hr on at e, m et hy l 3- O -c aff eo yl -2 -C -m et hy l O O H O H O O O O H O H Le av es (Ja pa n) [1 01 ] 16 5 4- (A ce ty lo xy )- 3- [[ 3- (3 ,4 - di hy dr ox yp he ny l)- 1-o xo -2 -p ro pe n- 1-y l-] ox y] -2 -h yd ro xy - 2- m et hy l-b ut an oi ca ci d O H O O H O O H O H O O O N ot fo un d (Ja pa n) [7 3] 16 6 3- (3 ,4 -D ih yd ro xy ph en yl )- te tr ah yd ro -4 - hy dr ox y- 4- m et hy l-5 -o xo -3 -fu ra ny l es te r- 2- pr op en oi ca ci d 3- O -C aff eo yl -2 -C -m et hy l- D -e ry th ro no -1 ,4 -la ct on e H O H O O O O O O H Le av es (Ja pa n) [1 01 ] 16 7 3- [[ 3- (3 ,4 -D ih yd ro xy ph en yl )- 1-o xo -2 - pr op en -1- yl ]- ox y] -1 ,4 ,5 - tr ih yd ro xy -c yc lo he xa ne ca rb ox yl ic ac id Ch lo ro ge ni ca ci d O H O H O O H O O H O O H H O Ae ria l( Ja pa n) ;w ho le (T ai w an ) [7 0, 71 ,7 5] 32 Evidence-Based Complementary and Alternative Medicine Ta bl e 7: C on tin ue d. S. N . IU PA C na m es C om m on na m es St ru ct ur e Pl an tp ar t( co un tr y) Re fe re nc es 16 8 4- [[ 3- (3 ,4 -D ih yd ro xy ph en yl )- 1-o xo -2 - pr op en -1- yl ]o xy ]- 1,3 ,5 -tr ih yd ro xy -c yc lo he xa ne ca rb ox yl ic ac id 4- O -C aff eo yl qu in ic ac id O H O H O O H O H O O O H O H Ae ria l( Ja pa n) [7 1] 16 9 3, 4- bi s[ [2 (E )- 3- (3 ,4 -D ih yd ro xy ph en yl )- 1-o xo -2 -p ro pe n- 1-y l]- ox y] -1 ,5 - di hy dr ox y- cy clo he xa ne ca rb ox yl ic ac id 3, 4- D i-O -c aff eo yl qu in ic ac id H O H O O O O O O H O H H O O H O H O Ae ria l( Ja pa n) ;W ho le (T ai w an ) [4 5, 49 ,7 0, 71 ] 17 0 3, 4- bi s[ [2 (E )- 3- (3 ,4 -D ih yd ro xy ph en yl )- 1-o xo -2 -p ro pe n- 1-y l]- ox y] -1 ,4 -d ih yd ro xy - cy clo he xa ne ca rb ox yl ic ac id 3, 5- D i-O -c aff eo yl qu in ic ac id H O H O O O H O O H O O H O O O HO H Ae ria l( Ja pa n) ;w ho le (T ai w an ) [4 5, 49 ,7 0, 71 ] Evidence-Based Complementary and Alternative Medicine 33 Ta bl e 7: C on tin ue d. S. N . IU PA C na m es C om m on na m es St ru ct ur e Pl an tp ar t( co un tr y) Re fe re nc es 17 1 3, 4- bi s[ [( 2E )- 3- (3 ,4 -D ih yd ro xy ph en yl )- 1- ox o- 2- pr op en -1- yl ]o xo ]- 1,5 -d ih yd ro xy - cy clo he xa ne ca rb ox yl ic ac id 4, 5- D i-O -c aff eo yl qu in ic ac id O H O O H H O O O O H O H O O H H O O W ho le (T ai w an ) [4 5, 49 ,7 0] 17 2 3- [4 -[ [- 6- O -[ 3- (4 -H yd ro xy ph en yl )- 1-o xo -2 -p ro pe n- 1-y l]-  -D - gl uc op yr an os yl ]- ox y] -p he ny l]- 2- pr op en oi ca ci d  -D -p -C ou m ar ic ac id ,4 -O - (6 -O -p -c ao um ar oy l- gl uc op yr an os yl ) H O O O H H O H H O H H O H H O O O Le av es (Ja pa n) [5 9] 17 3 3- [4 -[ [2 -O -A ce ty l-6 -O -[ 3- (4 - hy dr ox yp he ny l)- 1-o xo -2 -p ro pe n- 1-y l]-  -D - gl uc op yr an os yl ]- ox y] ph en yl ]2 -p ro pe no ic ac id  -D -p -C ou m ar ic ac id ,4 -O - (2 -O -a ce ty l-6 -O -p - ca ou m ar oy l- gl uc op yr an os yl ) H O O O H H O H H O H H O H O O O Le av es (Ja pa n) ;a er ia l (C hi na ) [3 4, 59 ] 17 4 6, 7- D ih yd ro xy -2 -c hr om en on e Es cu le tin ,c ic ho rig en in O H O H O O N ot fo un d (E gy pt ) [3 9] 34 Evidence-Based Complementary and Alternative Medicine Table 8: Aromatic compounds isolated from B. pilosa [30]. S. N. IUPAC names Common names Structure Plant part(country) References 175 1,2-Benzenediol Pyrocatechin HO HO Whole (Japan) [99] 176 4-Ethyl-1,2-benzenediol Pyrocatechol OH OH Whole (Japan) [99] 177 Dimethoxyphenol;2,6-dimethoxyphenol O HO O Roots (Japan) [99] 178 4-Ethenyl-2-methoxy-phenol p-Vinylguaiacol O OH Whole (Japan) [99] 179 2-Hydroxy-6-methylbenzaldehyde 6-Methyl- salicylaldehyde O OH Whole (Japan) [99] 180 Benzene-ethanol 2-Phenyl-ethanol HO Whole (Japan) [57] 181 4-Hydroxy-3-methoxy-benzaldehyde Vanillin O O HO Aerial (Japan) [99] 182 3-Hydroxy-4-methoxy-benzaldehyde Vanillin, iso O O OH Leaves (Japan) [99] 183 4-Hydroxybenzoic acid p-Hydroxybenzoicacid O HO OH Whole (Japan) [99] 184 2-Hydroxybenzoic acid Salicylic acid O HO HO Stem and roots (Japan) [99] 185 3,4-Dihydroxybenzoicacid Protocatechuic acid O HO OH OH Whole (Japan) [99] 186 4-Hydroxy- 3methoxybenzoic acid Vanillic acid O OH O OH Aerial (Uganda); Roots (Japan) [68, 99] Evidence-Based Complementary and Alternative Medicine 35 Table 8: Continued. S. N. IUPAC names Common names Structure Plant part(country) References 187 3,4,5-Trihydroxybenzoicacid Gallic acid O OH HO HO HO Whole (China) [102] [88]. This work supports the use of B. pilosa as an anti- inflammatory agent; however, no compounds responsible for the anti-inflammatory activity of B. pilosa were identified. A further study also reported the anti-inflammatory activity as well as the antiallergic activity of B. pilosa [75]. In this study, dried powder of the aerial part of B. pilosa, which had been pretreated with the enzyme cellulosine, was used for further tests. The results showed that oral administration of the cellulosine-treated B. pilosa lowered the level of serum IgE in mice 10 days after immunization with DNP (2,4- dintrophenyl)-Ascaris as an antigen. This treatment also reduced dye exudation in skin induced by passive cutaneous anaphylaxis and production of inflammatory mediators, his- tamine, and substance P in rats [75]. Phytochemical analysis showed that cellulosine treatment increased the percentage of caffeic acid and flavonoids. This study suggests that B. pilosa and its phenolics have anti-inflammatory functions. Phenolics and polyynes are major anti-inflammatory phytochemicals present in B. pilosa (Table 11). Unsurpris-6 ingly, phenolics such as luteolin (103) and ethyl caffeate (161) that are major constituents of B. pilosa have also been reported to possess anti-inflammatory activity. Lute- olin was reported to exhibit anti-inflammatory activity in macrophages. Xagorari and colleagues showed that luteolin inhibited the release of inflammatory cytokines, TNF- and interleukin-6, in RAW 264.7 cells following LPS stimulation [87]. It inhibited TNF- production with an IC 50 value of 1M. The underlying anti-inflammatory mechanism of luteolin was reported to be the inactivation of Akt and NF-B activation [87]. In addition, luteolin was reported to confer anti-inflammatory activity through inhibition of LPS-stimulated iNOS expression in BV-2 microglial cells. It inhibited LPS-activated microglia in a dose-dependent manner with an IC 50 value of 6.9 M.Moreover, immunoblot and RT-PCR data proved that luteolin suppressed IB- degradation and iNOS expression in LPS-activated microglia [85]. Kim and colleagues stated that luteolin may have beneficial effects on inflammatory neural diseases through inhibition of iNOS expression [85]. A related study revealed that luteolin decreased the transcriptional activity of NF-B RelA via partial inhibition of TNF-mediated NF-B DNA binding activity. Luteolin also inhibited Akt phosphorylation and induced degradation of a transcription factor, interferon regulatory factor (IRF) [86]. Chiang and colleagues showed that ethyl caffeate (161) significantly inhibited NO production in mouse macrophages, RAW 264.7 cells [84]. Based on MTT assays, they concluded that this inhibition was not due to the cytotoxicity of ethyl caffeate. The IC 50 value of ethyl caffeate in the inhibition of NO production was 5.5 g/mL, slightly lower than curcumin (positive control) which has an IC 50 value of 6.5g/mL. They demonstrated that ethyl caffeate exerted anti-inflammatory activity via the reduced transcription and translation of iNOS (inducible nitric oxide synthase) in RAW 246.7 cells. In addition, this compound also suppressed COX-2 expression in RAW 246.7 cells and MCF-7 cells. The in vivo anti-inflammatory effect of ethyl caffeate was verified by testing in TPA-treated mouse skin. Like celecoxib, the positive control, ethyl caffeate significantly abolished COX-2 expression in a dose-dependent manner. Ethyl caffeate at 1mg/200L/site (24mM) inhibited COX-2 expression at a level comparable to celecoxib at 1mg/200L/site (13mM). Remarkably, ethyl caffeate at 48mM (2mg/200L/site) was more effective than celecoxib at 131mM (10mg/200L/site). Moreover, this compound inhibited the activation of nuclear factor-B (NF-B) by LPS via the prevention of NF-B binding to DNA [84]. In addition, 3 ethyl caffeate analogs (ethyl 3,4- dihydroxyhydrocinnamate, ethyl cinnamate, and catechol) also showed different degrees of NF-B binding to DNA as listed in Table 12. Ethyl cinnamate lacks a catechol moiety which results in ineffective inhibition of NF-B binding to DNA [84]. Pereira and colleagues assessed the anti- 7 inflammatory and immunomodulatory activities of B. pilosa methanol extract as well as one polyyne, 2-O--glucosyltrideca-11(E)-en-3, 5,7,9-tetrayn-1,2-diol (54) in T lymphocytes and a zymosan-induced arthritis mouse model [27].